Total Payments
$3,447
2024 Payments
$527.13
Companies
27
Transactions
160
Medicare Patients
2,546
Medicare Billing
$627,590
Payment Breakdown by Category
Food & Beverage$3,195 (92.7%)
Education$252.74 (7.3%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,195 | 150 | 92.7% |
| Education | $252.74 | 10 | 7.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | $676.38 | 33 | $0 (2024) |
| Amgen Inc. | $482.57 | 15 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $316.07 | 19 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $291.97 | 8 | $0 (2023) |
| Fresenius USA Marketing, Inc. | $271.14 | 15 | $0 (2024) |
| Horizon Therapeutics plc | $172.25 | 7 | $0 (2023) |
| Mallinckrodt Hospital Products Inc. | $157.10 | 5 | $0 (2024) |
| Vifor Pharma, Inc. | $113.65 | 5 | $0 (2023) |
| Daiichi Sankyo Inc. | $111.38 | 4 | $0 (2019) |
| OPKO Pharmaceuticals, LLC | $107.97 | 6 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $527.13 | 20 | Amgen Inc. ($212.84) |
| 2023 | $545.59 | 22 | Otsuka America Pharmaceutical, Inc. ($111.74) |
| 2022 | $293.95 | 13 | Fresenius USA Marketing, Inc. ($81.75) |
| 2021 | $491.60 | 27 | AstraZeneca Pharmaceuticals LP ($125.42) |
| 2020 | $153.55 | 7 | Otsuka America Pharmaceutical, Inc. ($64.95) |
| 2019 | $532.71 | 29 | Otsuka America Pharmaceutical, Inc. ($174.50) |
| 2018 | $593.30 | 23 | Otsuka America Pharmaceutical, Inc. ($152.06) |
| 2017 | $309.43 | 19 | Amgen Inc. ($81.84) |
All Payment Transactions
160 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Food and Beverage | In-kind items and services | $29.20 | General |
| 11/11/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $29.01 | General |
| Category: DIABETES | ||||||
| 11/07/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $26.53 | General |
| Category: Diabetes | ||||||
| 11/06/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $24.46 | General |
| Category: Nephrology | ||||||
| 10/08/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $15.81 | General |
| 10/03/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $23.70 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/03/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $23.70 | General |
| Category: Inflammation/Rare Disease | ||||||
| 09/16/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $16.27 | General |
| Category: IMMUNOLOGY | ||||||
| 09/12/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $14.17 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/10/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $26.76 | General |
| Category: NEPHROLOGY | ||||||
| 09/05/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $25.13 | General |
| Category: IMMUNOLOGY | ||||||
| 08/07/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $33.31 | General |
| Category: Inflammation/Rare Disease | ||||||
| 07/15/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $16.64 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 07/11/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $28.43 | General |
| Category: Cardio-renal | ||||||
| 06/18/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $121.84 | General |
| Category: Inflammation | ||||||
| 05/30/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $4.28 | General |
| Category: Inflammation/Rare Disease | ||||||
| 03/25/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $20.21 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/13/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $21.91 | General |
| Category: Phosphate binder for ESRD | ||||||
| 03/07/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $6.01 | General |
| Category: Inflammation/Rare Disease | ||||||
| 03/04/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $19.76 | General |
| Category: Phosphate binder for ESRD | ||||||
| 12/05/2023 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $28.16 | General |
| Category: NEPHROLOGY | ||||||
| 11/20/2023 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $31.34 | General |
| Category: IMMUNOLOGY | ||||||
| 11/14/2023 | GlaxoSmithKline, LLC. | JESDUVROQ (Drug) | Food and Beverage | In-kind items and services | $12.69 | General |
| Category: NEPHROLOGY | ||||||
| 11/06/2023 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Food and Beverage | In-kind items and services | $19.19 | General |
| Category: HEMATOLOGY | ||||||
| 10/24/2023 | Amgen Inc. | Aranesp (Biological), Parsabiv, TAVNEOS | Food and Beverage | In-kind items and services | $25.04 | General |
| Category: Nephrology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 653 | 1,391 | $375,666 | $175,202 |
| 2022 | 13 | 721 | 1,527 | $347,843 | $184,444 |
| 2021 | 13 | 628 | 1,194 | $275,040 | $150,163 |
| 2020 | 11 | 544 | 1,081 | $252,552 | $117,780 |
Total Patients
2,546
Total Services
5,193
Medicare Billing
$627,590
Procedure Codes
49
All Medicare Procedures & Services
49 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 47 | 277 | $156,505 | $75,153 | 48.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 151 | 402 | $48,129 | $24,463 | 50.8% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2023 | 36 | 92 | $43,240 | $21,177 | 49.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 151 | 241 | $50,128 | $20,705 | 41.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 104 | 125 | $30,000 | $11,967 | 39.9% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2023 | 54 | 121 | $14,520 | $6,562 | 45.2% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 22 | 25 | $8,550 | $4,170 | 48.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 32 | 32 | $8,672 | $3,923 | 45.2% |
| 90962 | Dialysis services, 1 physician visit per month (20 years or older) | Office | 2023 | 15 | 18 | $7,200 | $2,862 | 39.8% |
| 90945 | Dialysis procedure including 1 evaluation | Facility | 2023 | 13 | 24 | $3,192 | $1,601 | 50.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 12 | 16 | $2,884 | $1,491 | 51.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 16 | 18 | $2,646 | $1,128 | 42.6% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 50 | 324 | $162,000 | $91,192 | 56.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 178 | 471 | $52,198 | $25,793 | 49.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 125 | 203 | $33,641 | $17,764 | 52.8% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 117 | 136 | $28,752 | $13,979 | 48.6% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2022 | 26 | 45 | $20,250 | $10,727 | 53.0% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2022 | 70 | 163 | $19,560 | $9,230 | 47.2% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 28 | 30 | $10,260 | $4,814 | 46.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 21 | 21 | $6,436 | $3,257 | 50.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 34 | 39 | $4,305 | $2,398 | 55.7% |
| 90945 | Dialysis procedure including 1 evaluation | Facility | 2022 | 13 | 24 | $2,880 | $1,469 | 51.0% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 34 | 45 | $3,150 | $1,360 | 43.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 12 | 12 | $2,192 | $1,354 | 61.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 13 | 14 | $2,219 | $1,107 | 49.9% |
About Dr. Michael Dirusso, D.O
Dr. Michael Dirusso, D.O is a Nephrology healthcare provider based in Schenectady, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/12/2009. The National Provider Identifier (NPI) number assigned to this provider is 1700023868.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Dirusso, D.O has received a total of $3,447 in payments from pharmaceutical and medical device companies, with $527.13 received in 2024. These payments were reported across 160 transactions from 27 companies. The most common payment nature is "Food and Beverage" ($3,195).
As a Medicare-enrolled provider, Dirusso has provided services to 2,546 Medicare beneficiaries, totaling 5,193 services with total Medicare billing of $627,590. Data is available for 4 years (2020–2023), covering 49 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Location Schenectady, NY
- Active Since 01/12/2009
- Last Updated 07/16/2015
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1700023868
Products in Payments
- JYNARQUE (Drug) $503.26
- KRYSTEXXA (Biological) $263.25
- Velphoro (Drug) $247.52
- LOKELMA (Drug) $243.72
- Veltassa (Drug) $209.15
- SOLIRIS (Drug) $208.47
- SAMSCA (Drug) $173.12
- ACTHAR (Biological) $155.33
- Parsabiv (Biological) $135.89
- TAVNEOS (Drug) $121.84
- INJECTAFER (Drug) $111.38
- RAYALDEE (Drug) $92.07
- BENLYSTA (Biological) $91.98
- Auryxia (Drug) $85.93
- Parsabiv (Drug) $84.73
- Kerendia (Drug) $75.22
- AURYXIA (Drug) $63.42
- Rituxan (Biological) $60.62
- JARDIANCE (Drug) $55.54
- FARXIGA (Drug) $36.85
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.